Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 19, 2026 (5 months ago)

Clomiphene Citrate USP Active Pharmaceutical Ingredient

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), Net Weight a)1 KG (NDC 84849-000-01), b) 500 g (NDC 84849-000-02), (c) 100 g (NDC 84849-000-03), Rx Only, Shimoga Chemicals Address -W-57A, MIDC Kupwad Samgli, Maharashtra, 416436, India.

Drug: Clomiphene

Recalling firm
Shimoga Chemicals
NDC code
84849-000-01
Origin
N/A, India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0691-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Clomiphene recalls

See all
Class III · Low risk

ClomiPHENE CITRATE Tablets

Chemical Contamination: impurity failure due to chemical contamination of the active ingredient.

Terminated Chemical / undeclared EMD Serono, Inc. NDC 0093-0041-03 D-1813-2015
Class II · Moderate risk

Clomiphene Citrate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-594-2015

Other cgmp deviation recalls from 2026

All cgmp deviation recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP deviations: tablets with black specks.

Ongoing cGMP deviation Golden State Medical Supply Inc. NDC 51407-215-10 D-0771-2026